Tella Inc
TSE:2191

Watchlist Manager
Tella Inc Logo
Tella Inc
TSE:2191
Watchlist
Price: 2 JPY -50% Market Closed
Market Cap: 101.3m JPY

Tella Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Tella Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Tella Inc
TSE:2191
Cash from Operating Activities
-ÂĄ813.6m
CAGR 3-Years
8%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Carna Biosciences Inc
TSE:4572
Cash from Operating Activities
-ÂĄ2.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-23%
C
Chiome Bioscience Inc
TSE:4583
Cash from Operating Activities
-ÂĄ996.3m
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
4%
Medinet Co Ltd
TSE:2370
Cash from Operating Activities
-ÂĄ1.4B
CAGR 3-Years
-7%
CAGR 5-Years
-17%
CAGR 10-Years
1%
CellSource Co Ltd
TSE:4880
Cash from Operating Activities
ÂĄ333.1m
CAGR 3-Years
-27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immuno-Biological Laboratories Co Ltd
TSE:4570
Cash from Operating Activities
ÂĄ183.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Tella Inc
Glance View

tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. The company is headquartered in Shinjuku, Tokyo-To and currently employs 30 full-time employees. The company went IPO on 2009-03-26. The firm operates through three business segments. The Cell Medicine segment is engaged in the provision of cancer treatment technology and operational method centered on dendritic cell vaccine therapy. This segment is also engaged in the provision of Services for contract medical institutions, such as cell culture system maintenance support services, management system maintenance support services and disease support services. The Medical Support segment is mainly engaged in the provision of drug development services (CROs) and genetic testing services. The Pharmaceutical segment is engaged in the development of the dendritic cell vaccine for regulatory approval as a product for cancer regenerative medicine.

Intrinsic Value
Not Available

See Also

What is Tella Inc's Cash from Operating Activities?
Cash from Operating Activities
-813.6m JPY

Based on the financial report for Mar 31, 2022, Tella Inc's Cash from Operating Activities amounts to -813.6m JPY.

What is Tella Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-8%

Over the last year, the Cash from Operating Activities growth was 30%. The average annual Cash from Operating Activities growth rates for Tella Inc have been 8% over the past three years , -8% over the past five years .

Back to Top